Orchard Therapeutics

$15.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.47 (3.13%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ORTX and other stocks, options, ETFs, and crypto commission-free!

About ORTX

Orchard Therapeutics plc American Depositary Shares, also called Orchard Therapeutics, is a biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of gene therapies. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Read More Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). It operates through the following geographical segments: United Kingdom, European Union, and United States. The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Employees
180
Headquarters
London, Greater London
Founded
2018
Market Cap
1.45B
Price-Earnings Ratio
Dividend Yield
Average Volume
346.87K
High Today
$15.64
Low Today
$14.85
Open Price
$15.05
Volume
186.12K
52 Week High
$21.64
52 Week Low
$8.65

Collections

ORTX Earnings

-$0.56
-$0.49
-$0.42
-$0.35
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.